<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003218.pub2" GROUP_ID="NEUROMUSC" ID="535800031817083790" MERGED_FROM="" MODIFIED="2011-01-19 17:59:48 +0100" MODIFIED_BY="Kate Jewitt" REVIEW_NO="040" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2011-01-19 17:59:48 +0100" MODIFIED_BY="Kate Jewitt">
<TITLE>Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy</TITLE>
<CONTACT MODIFIED="2011-01-19 17:59:48 +0100" MODIFIED_BY="Kate Jewitt"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@rpc.ap-hop-paris.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-01-19 17:59:48 +0100" MODIFIED_BY="Kate Jewitt"><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@rpc.ap-hop-paris.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON><PERSON ID="15416" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dan</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Moore</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>dmoore@cc.ucsf.edu</EMAIL_1><EMAIL_2>dmoore@cc.ucsf.edu</EMAIL_2><ADDRESS><DEPARTMENT>Research Institute</DEPARTMENT><ORGANISATION>California Pacific Medical Center</ORGANISATION><ADDRESS_1>475 Brannan St Suite 220</ADDRESS_1><CITY>San Francisco</CITY><ZIP>94107</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>00 1 415 600 1567</PHONE_1><FAX_1>00 1 415 600 1725</FAX_1></ADDRESS></PERSON><PERSON ID="4842" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Miller</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Director</POSITION><EMAIL_1>millerrx@sutterhealth.org</EMAIL_1><ADDRESS><DEPARTMENT>Forbes Norris ALS Research Center</DEPARTMENT><ORGANISATION>California Pacific Medical Center</ORGANISATION><ADDRESS_1>2324 Sacramento Street, Suite 150</ADDRESS_1><CITY>San Francisco</CITY><ZIP>94115</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 415 600 3604</PHONE_1><PHONE_2>+415 600 3935</PHONE_2><FAX_1>1 415 923 6567</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-11-01 08:45:51 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="10" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="10" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="10" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2010-12-14 12:09:04 +0000" MODIFIED_BY="Kate Jewitt">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-14 12:09:04 +0000" MODIFIED_BY="Kate Jewitt">
<DATE DAY="24" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>We have changed the statistical analysis and used generic inverse variance given that most of trials have a cross-over design</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-14 12:09:04 +0000" MODIFIED_BY="Kate Jewitt">
<DATE DAY="29" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>New searches June 2009. Two new included studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-09-29 13:03:47 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-29 13:03:47 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="2" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-07-02 19:17:41 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="4" YEAR="2006"/>
<DESCRIPTION>
<P>This review was substantively updated in 2006 to incorporate evidence from two new trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-02-10 11:18:19 +0000" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2010-02-10 11:18:19 +0000" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2010-02-10 11:18:19 +0000" MODIFIED_BY="Ruth Brassington">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-02-10 11:18:12 +0000" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2010-02-10 11:18:12 +0000" MODIFIED_BY="Ruth Brassington">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-01-19 16:58:59 +0000" MODIFIED_BY="Kate Jewitt">
<SUMMARY MODIFIED="2010-12-14 12:39:10 +0000" MODIFIED_BY="Kate Jewitt">
<TITLE>Drugs that increase alertness (psychostimulants) for excessive daytime sleepiness (hypersomnia) in myotonic dystrophy</TITLE>
<SUMMARY_BODY MODIFIED="2010-12-14 12:39:10 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-09-30 10:27:00 +0100&quot; modified_by=&quot;Richard Hughes&quot; class=&quot;inserted&quot;&gt;Four trials are mentioned in the abstract but only th&lt;/span&gt;&lt;span modified=&quot;2009-09-30 10:28:00 +0100&quot; modified_by=&quot;Richard Hughes&quot; class=&quot;inserted&quot;&gt;ree here. Please can the authors revise or explain the discrepancy&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-12-14 12:39:10 +0000" NOTES_MODIFIED_BY="Kate Jewitt">
<P>Myotonic dystrophy is an inherited muscular dystrophy causing muscle weakness and wasting. Many people with myotonic dystrophy complain about excessive daytime sleepiness. This symptom is related to disordered central respiratory control. Psychostimulants are drugs that increase alertness and include caffeine, amphetamine, selegiline, methylphenidate and modafinil. In this updated review there were few randomized controlled trials which evaluated the efficacy and safety of psychostimulants in myotonic dystrophy. One randomized controlled trial of selegiline involving 11 participants did not demonstrate any benefit. Four studies of another drug modafinil suggested inconsistent and slight benefits. Only two of these studies used the gold standard test, a sleepiness scale, to evaluate hypersomnia and found non significant improvement. In these four studies modafinil seemed well tolerated. Further randomized trials are needed to determine the utility of psychostimulants for myotonic dystrophy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-01-19 16:50:56 +0000" MODIFIED_BY="Kate Jewitt">
<ABS_BACKGROUND>
<P>Excessive daytime sleepiness is a common symptom of myotonic dystrophy. Psychostimulants are drugs increasingly used to treat hypersomnia in myotonic dystrophy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-01-19 16:50:54 +0000" MODIFIED_BY="Kate Jewitt">
<P>To search systematically for, and combine all evidence from, randomized trials relating to the effects of psychostimulants in myotonic dystrophy patients with hypersomnia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-01-19 16:50:55 +0000" MODIFIED_BY="Kate Jewitt">
<P>We searched the Cochrane Neuromuscular Disease Specialized Register (October 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (19 October 2010, issue 4, 2010 in <I>the Cochrane Library</I>), MEDLINE (January 1966 to October 2010) and EMBASE (January 1980 to October 2010) for randomized trials concerning psychostimulants in myotonic dystrophy, checked the bibliographies of identified papers and made enquiries of the authors of the papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-01-19 16:50:56 +0000" MODIFIED_BY="Kate Jewitt">
<P>We considered all randomized or quasi-randomized trials that have evaluated any type of psychostimulant (versus a placebo or no treatment) in children or adults with proven myotonic dystrophy and hypersomnia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-12-14 12:39:10 +0000" MODIFIED_BY="Kate Jewitt">
<P>Potentially relevant papers were scrutinized by two authors and the selection of eligible studies was agreed by them and a third author. Data were extracted by one author and checked by a second author.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-12-14 12:37:25 +0000" MODIFIED_BY="Kate Jewitt">
<P>
<B>Primary outcome</B>
<BR/>Mean improvement in the maintenance of wakefulness test was available for two of the five identified trials accounting for 48 participants. The mean difference +2.52(95% confidence interval (CI) -2.32 to +7.37), was not significant and there was marked heterogeneity across these studies (I<SUP>2</SUP>= 50%).</P>
<P>
<B>Secondary outcomes</B>
<BR/>Mean improvement in the Epworth Sleepiness Scale was available in four trials accounting for 101 participants. The mean difference was -2.26 (95% CI -3.78to -0.73), significantly in favor of modafinil with marked heterogeneity across the studies (I<SUP>2</SUP>= 84%). There was no evidence for any treatment benefit on the multiple sleep latency test or quality of life.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-12-14 12:39:10 +0000" MODIFIED_BY="Kate Jewitt">
<P>There is low quality evidence from two small trials that psychostimulants do not significantly improve the maintenance of wakefulness test in myotonic dystrophy. There is low quality evidence from four studies that modafinil significantly improves the Epworth Sleepiness Scale. More randomized trials are needed to evaluate the efficacy and safety of psychostimulants.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-01-19 16:58:59 +0000" MODIFIED_BY="Kate Jewitt">
<BACKGROUND MODIFIED="2010-12-14 12:37:56 +0000" MODIFIED_BY="Kate Jewitt">
<P>Myotonic dystrophy is the most common form of adult muscular dystrophy, with a prevalence of one in 8000 (<LINK REF="REF-Harper-1979" TYPE="REFERENCE">Harper 1979</LINK>). This multisystem disorder is dominantly inherited and caused by amplification of an unstable trinucleotide (CTG)n repeat (<LINK REF="REF-Brook-1992" TYPE="REFERENCE">Brook 1992</LINK>; <LINK REF="REF-Buxton-1992" TYPE="REFERENCE">Buxton 1992</LINK>; <LINK REF="REF-Fu-1992" TYPE="REFERENCE">Fu 1992</LINK>; <LINK REF="REF-Harley-1992" TYPE="REFERENCE">Harley 1992</LINK>; <LINK REF="REF-Mahadevan-1992" TYPE="REFERENCE">Mahadevan 1992</LINK>) in a transcript encoding a serine/threonine kinase, the dystrophia myotonica-protein kinase (<LINK REF="REF-Dunne-1994" TYPE="REFERENCE">Dunne 1994</LINK>). The mechanisms by which the expanded trinucleotide repeat causes a dominant biochemical defect and the varied clinical phenotype are unknown.</P>
<P>Excessive daytime somnolence or hypersomnia has long been recognized as a prominent symptom of myotonic dystrophy (<LINK REF="REF-Gillam-1964" TYPE="REFERENCE">Gillam 1964</LINK>; <LINK REF="REF-Harper-1979" TYPE="REFERENCE">Harper 1979</LINK>), and has been documented in 40 to 50% of people with the disease (<LINK REF="REF-Manni-1991" TYPE="REFERENCE">Manni 1991</LINK>; <LINK REF="REF-Rubinsztein-1998" TYPE="REFERENCE">Rubinsztein 1998</LINK>). The mechanisms of somnolence in myotonic dystrophy are not fully understood. However, it is clear from several studies that hypersomnia is not related to the degree of muscular disability or the degree of hypercapnia that might result from associated respiratory weakness (<LINK REF="REF-B_x00e9_gin-1997" TYPE="REFERENCE">Bégin 1997</LINK>; <LINK REF="REF-Gillam-1964" TYPE="REFERENCE">Gillam 1964</LINK>; <LINK REF="REF-Guilleminault-1978" TYPE="REFERENCE">Guilleminault 1978</LINK>; <LINK REF="REF-Manni-1991" TYPE="REFERENCE">Manni 1991</LINK>). In addition, the daytime somnolence is not related to the disturbance of sleep pattern or night time breathing abnormalities which are common in myotonic dystrophy (<LINK REF="REF-Gilmartin-1991" TYPE="REFERENCE">Gilmartin 1991</LINK>; <LINK REF="REF-Manni-1991" TYPE="REFERENCE">Manni 1991</LINK>; <LINK REF="REF-Van-der-Mech_x00e9_-1994" TYPE="REFERENCE">Van der Meché 1994</LINK>). Loss of serotonin-containing neurons in the median raphe of people with myotonic dystrophy who had daytime somnolence argues strongly in favor of a central origin for the hypersomnia (<LINK REF="REF-Ono-1998" TYPE="REFERENCE">Ono 1998</LINK>).</P>
<P>In an observational study, the central stimulant methylphenidate produced sustained (up to two to six years) improvement in daytime sleepiness in 7 out of 11 participants with myotonic dystrophy (<LINK REF="REF-Van-der-Mech_x00e9_-1994" TYPE="REFERENCE">Van der Meché 1994</LINK>). Another open-label trial conducted in 11 participants with myotonic dystrophy showed that prolonged treatment (16.4 weeks on average) with 200 to 400 mg of modafinil significantly improved daytime sleepiness (<LINK REF="REF-Damian-2001" TYPE="REFERENCE">Damian 2001</LINK>).</P>
<P>This systematic review was designed to determine the extent and quality of the evidence for the role of psychostimulants in the management of hypersomnia in myotonic dystrophy.<BR/>
</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-12-14 12:39:13 +0000" MODIFIED_BY="Kate Jewitt">
<P>The primary aim of the present systematic review was to search systematically for, and combine all evidence from, randomized trials relating to the effects of psychostimulants in myotonic dystrophy patients with hypersomnia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-01-19 16:53:17 +0000" MODIFIED_BY="Kate Jewitt">
<SELECTION_CRITERIA MODIFIED="2010-12-14 12:46:25 +0000" MODIFIED_BY="Kate Jewitt">
<CRIT_STUDIES MODIFIED="2010-12-14 12:46:25 +0000" MODIFIED_BY="Kate Jewitt">
<P>All randomized or quasi-randomized trials with or without blinding were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children and adults who met the established clinical and electromyographic criteria for myotonic dystrophy (<LINK REF="REF-Griggs-1989" TYPE="REFERENCE">Griggs 1989</LINK>) were considered. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All psychostimulants, including caffeine, amphetamine, methylphenidate, selegiline, modafinil, were considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-12-14 12:37:58 +0000" MODIFIED_BY="Kate Jewitt">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-12-14 12:37:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>Mean improvement in the maintenance of wakefulness test. The maintenance of wakefulness test is a standardized tool to evaluate hypersomnia and consists usually of five polygraphic recordings at two-hour intervals made on the day after an overnight polysomnography. During each recording the patient is in the sitting position and is asked to stay awake, and sleep latencies are calculated from the four first recordings (<LINK REF="REF-Mitler-1982" TYPE="REFERENCE">Mitler 1982</LINK>). Results are expressed in minutes with higher scores representing reduced hypersomnia.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-12-14 12:09:04 +0000" MODIFIED_BY="Kate Jewitt">
<OL>
<LI>Mean improvement in a sleepiness scale, such as the Epworth Sleepiness Scale (<LINK REF="REF-Johns-1991" TYPE="REFERENCE">Johns 1991</LINK>).</LI>
<LI>Mean improvement in the multiple sleep latency test. The multiple sleep latency test is a standardized tool to evaluate hypersomnia and consists usually of four polygraphic recordings at two hour intervals made on the day after an overnight polysomnography. During each recording the patient is lying in the recumbent position, asked to sleep and is allowed 20 minutes to fall asleep, and sleep latencies are calculated (<LINK REF="REF-Carskadon-1986" TYPE="REFERENCE">Carskadon 1986</LINK>). The results are expressed in minutes with lower scores representing hypersomnia.</LI>
<LI>Ambulatory 24 hour sleep-wake monitoring.</LI>
<LI>Sleep studies, i.e. apnea-hypopnea index or mean oxygen saturation or the time spent with an arterial oxygen saturation below 90%.</LI>
<LI>Quality of life, as assessed for example by the SF36, for which we computed a total score by summing the mental and physical component.</LI>
<LI>Adverse events.</LI>
</OL>
<P>The primary and the secondary outcomes were recorded separately after two to four weeks (short-term effects) and after six to 12 months (long-term effects) following treatment initiation.</P>
<SUBSECTION>
<HEADING LEVEL="5">Main outcomes for 'Summary of findings' table</HEADING>
<P>The main outcomes to be included in the 'Summary of findings' tables included the maintenance of wakefulness test, the Epworth Sleepiness Scale, the multiple sleep latency test and quality of life.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-12-14 12:11:11 +0000" MODIFIED_BY="Kate Jewitt">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register with 'myotonic dystrophy' OR 'Steinert disease' OR 'dystrophia myotonica' OR 'myotonia atrophica' AND 'hypersomnia' OR 'somnolence' OR 'sleepiness' AND 'central stimulants' OR 'psychostimulants' OR 'caffeine' OR 'amphetamine' OR 'methylphenidate' OR 'selegiline' OR 'modafinil' as search terms.</P>
<P>All references in the identified trial were checked. Contact with the authors of the only trial we found in the original version of the review did not identify any additional published or unpublished data.</P>
<SUBSECTION>
<HEADING LEVEL="3">Electronic search strategies</HEADING>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (19 October 2010, Issue 4, 2010 in <I>the Cochrane Library), </I>MEDLINE (January 1966 to October 2010), and EMBASE (January 1980 to October 2010). The strategies are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-01-19 16:53:17 +0000" MODIFIED_BY="Kate Jewitt">
<STUDY_SELECTION MODIFIED="2011-01-19 16:53:17 +0000" MODIFIED_BY="Kate Jewitt">
<P>Two authors independently checked titles and abstracts identified from the database. Two authors obtained the full text of all studies of possible relevance for independent assessment. The authors decided which trials fitted the inclusion criteria, and graded their methodological quality. The authors resolved any disagreement by discussion between the authors. We contacted authors of trials for clarification where necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-12-14 12:17:32 +0000" MODIFIED_BY="Kate Jewitt">
<P>Two authors performed data extraction independently with specific data extraction forms and we contacted the authors of trials systematically to provide missing data where possible. One author (DA) entered data into the computer and the others checked the data entry.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-12-14 12:48:36 +0000" MODIFIED_BY="Kate Jewitt">
<P>Two authors assessed the risk of bias in the included trials independently, with particular emphasis on appropriateness of the sequence generation (YES = a random component in the sequence generation is described, NO = a non-random component is described, UNCLEAR = insufficient information is available), on appropriateness of treatment allocation concealment (YES = method used avoids that investigators foresee assignment; NO = Investigators could possibly foresee assignment; UNCLEAR = insufficient information is available). We also assessed the adequacy of blinding of participants, personnel and outcome assessors, and of addressing the issue of incomplete data assessment, and selective outcome reporting. Finally, we also checked other potential problems that may have resulted in a risk of bias, i.e. protocol violations, early stopping of the trial, extreme baseline imbalance, any other problem in the design or the conduct of the trial that was reported by the authors. Where there was uncertainty, we contacted authors of trials for clarification. We resolved any disagreement by discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-12-14 12:51:53 +0000" MODIFIED_BY="Kate Jewitt">
<P>For each outcome measure 2 x 2 tables, summarizing the number of people who experienced the event or outcome in each comparison group and the total number in each group, were computed. These tables were organized so that a beneficial effect of treatment was associated with a risk ratio (RR) &lt; 1 or a risk difference (RD) &lt; 0. Intention-to-treat analyses were performed. Statistical calculations were performed using Review Manager (RevMan) 5 when possible.</P>
</EFFECT_MEASURES>
<BIAS_ASSESSMENT MODIFIED="2010-02-10 10:55:28 +0000" MODIFIED_BY="Ruth Brassington">
<P>If sufficient studies had been discovered, evidence of publication bias was to be investigated using the funnel plot method.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-12-14 12:54:48 +0000" MODIFIED_BY="Kate Jewitt">
<P>A weighted treatment effect was to be calculated across trials. The results were to be expressed as risk ratios (RR) with 95% confidence intervals (CI), numbers needed to treat (NNT) for dichotomous outcomes and weighted mean differences (WMD and 95% CI) for continuous outcomes. When cross-over trials were included in the analysis, treatment effects were summarized as mean difference between treatment effects and standard error, and analyzed by general inverse variance (GIV). Methods based on a random-effects model were to be considered only in case of heterogeneity. If significant heterogeneity was found, sensitivity analysis was to be performed to identify the trials and the factors responsible (related to patient selection or treatment).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-02 19:25:22 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was to be performed considering sleep-apnea factors, obesity (defined by a body mass index above 28 kg/m<SUP>2</SUP>) and upper airway obstruction (i.e. nasal obstruction, long or hypertrophic soft palate, small jaw, retroposition of the jaw).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-12-14 13:00:52 +0000" MODIFIED_BY="Kate Jewitt">
<STUDY_DESCRIPTION MODIFIED="2010-12-14 12:39:21 +0000" MODIFIED_BY="Kate Jewitt">
<P>We first searched in May 2001 and found only one randomized controlled trial (<LINK REF="STD-Antonini-1997" TYPE="STUDY">Antonini 1997</LINK>). An update in January 2006 found two new potentially relevant studies (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>).</P>
<P>For the 2010 update, the number of papers found by the current strategies were: MEDLINE = 15 (8 new papers), EMBASE = 19 (7 new papers), NMD REGISTER = 6 (3 new papers), CENTRAL = 9. From these papers, for the 2010 update, we found two new relevant studies (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>; <LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>), making a total of five relevant randomized trials. Four trials had a cross-over design and one was conducted on parallel groups (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>). One study (<LINK REF="STD-Antonini-1997" TYPE="STUDY">Antonini 1997</LINK>) had 11 participants, but one dropped out because of poor compliance. Five participants were allocated to receive placebo for 30 days and then, after a 30-day washout period they received 20 mg daily of selegiline for another 30-day period. The remaining five participants were randomized to receive selegiline first and then after a 30-day washout period, placebo. The remaining four trials have investigated the efficacy and safety of modafinil (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>; <LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>; <LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>).</P>
<P>One study included 40 adults with myotonic dystrophy who were allocated to receive modafinil (or a placebo) at a dose of 100 mg every twelve hours for one week and then 100 mg in the morning and 200 mg in the evening for one week (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>). The primary efficacy variable in this study was the Epworth Sleepiness Scale. The authors used a modified version of the Epworth Sleepiness Scale from a 4-point ordinal scale to a 10-cm visual analogue scale, with the four descriptors (no chance of dozing, slight chance of dozing, moderate chance of dozing, high chance of dozing) centred at 0.5, 3.5, 6.5, and 9.5 cm. Patients made a single mark across the scale at the point corresponding to their perceived chance of falling asleep. Secondary endpoints were the Stanford Sleepiness Scale 17 (SSS), the vigour-activity and fatigue-inertia factors of the Profile of Mood States and the energy&#8211;fatigue scale from the RAND 36-Item Health Survey. Modafinil reduced the Epworth Sleepiness Scale score (248 mm on average, 95% CI 220 to 276 versus 309 mm, 95% CI 281 to 336 mm; P &lt; 0.001), and the Standford Sleepiness Scale score (3.05, 95% CI 2.77 to 3.33 versus 3.45, 95% CI 3.45 to 3.71; P &lt; 0.05). On the Profile of Mood State, modafinil decreased the fatigue-inertia score (P &lt; 0.001) and increased the vigour-activity and tension-activity score (P &lt; 0.001), with a decrease in the total mood disturbance score (P &lt; 0.05). On the RAND 36-Item Health Survey score, modafinil enhanced both quality of life measures of energy (P &lt; 0.001) and health change (P &lt; 0.05). In this study, 30 participants reported a total of 83 adverse events (65 on modafinil and 18 on placebo), mostly during the first week of treatment. Adverse events that were reported more than once included headache (n = 15), anorexia (n = 6), nausea (n = 6), insomnia (n = 5), anxiety (n = 4), dry mouth (n = 4), dyspepsia (n = 4), dizziness (n = 3), nervousness (n = 3), and tachycardia (n = 2). Four randomized participants withdrew, one during the placebo phase in the first week for a reason which was not drug related, and three withdrew due to adverse events, one in the placebo phase and two in the treatment phase.</P>
<P>Another study (<LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>) was conducted in 20 adults with myotonic dystrophy and an Epworth Sleepiness Scale score of 10 or more. The participants were allocated to modafinil or a placebo for two periods of four weeks each separated by a two-week washout period. Modafinil was given orally as a single morning dose of 100 mg for the first five days and of 200 mg for the remaining days (i.e. study days 6 to 28). This study had two primary outcome measures, the Epworth Sleepiness Scale and a modified maintenance of wakefulness test. This test involved the participants resisting sleep while lying semi-recumbent in a darkened room for a maximum of 40 minutes on three or four occasions during the day. The participants were asked to tap a proximity detector with a finger in response to a dim red light-emitting-diode flashing regularly every three seconds. Sleep was defined as a failure to respond for 21 seconds (or seven responses), and was not based upon electroencephalographic recording. This showed that modafinil reduced the Epworth Sleepiness Scale score slightly but not significantly. Medians varied from 14 to 11 with modafinil versus 13 to 14 with placebo, P = 0.185). At four weeks of treatment the Epworth Sleepiness Scale score was lower in the treated group than in the placebo group (medians, 11 versus 14, P = 0.049). The changes in the modified maintenance of wakefulness score were not significantly different between modafinil and placebo. Medians varied from 31.7 to 40 with modafinil and from 33.3 to 28.7 with placebo (P = 0.063). However, after four weeks of treatment the median score was higher in the modafinil arm compared to placebo arm (40 versus 28.7, P = 0.006). There was no significant difference between modafinil and placebo for secondary outcomes that included a driving stimulation test and the SF-36 quality of life scale. In this study, no participant withdrew due to adverse events, and one participant withdrew before the final visit for a reason which was not drug related.</P>
<P>A fourth study included 13 patients (<LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>). Treatments were given for two periods of two weeks, separated by a one-week washout period. Modafinil was given at the dose of 200 mg per day for the first week and the patients could double the dose during the second week. The primary outcome was the increase in spontaneous activity based on a structured interview of both the patient and the closest relative. The score based on the interview ranged from 0 (no improvement) to five (substantial improvement). Additional outcomes included the RAND-36 questionnaire, and the Epworth Sleepiness Scale. There was no evidence for any difference between treatment arms, except for the Epworth Sleepiness Scale (-3.7 versus 0.2, P = 0.015).</P>
<P>In the last study (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>), 28 patients with genetically proven myotonic dystrophy and an Epworth Sleepiness Scale of more than 10 and onset of sleep in multiple sleep latency test in 8 minutes or less were randomized to receive either modafinil or placebo at a dose of 300 mg per day for 4 weeks. The primary outcome was maintenance of wakefulness test. At four weeks, mean (SD) maintenance of wakefulness test was 15.8 (3.8) in the placebo group and 16.4 (3.3) in the modafinil group (P = 0.93). There was no evidence for a difference between the two groups for any secondary outcome. The differences in baseline and 4 week Epworth Sleepiness Scale values were derived from data provided by the study statistician.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-02-10 10:58:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>All five studies had low risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-12-14 13:00:52 +0000" MODIFIED_BY="Kate Jewitt">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome: mean improvement in the maintenance of wakefulness test</HEADING>
<P>This outcome was available in the short-term for two trials of modafinil accounting for 48 patients (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>). In one cross-over trial there were 19 participants who had two measurements (<LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>). The mean difference was 2.52 (95% CI: -2.32 to +7.37) (random-effects model) in favor of modafinil, and there was a strong heterogeneity across these studies (I² = 62%) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>Neither trial assessed this outcome in the long-term.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<P>None of the trials have assessed secondary outcomes in the long-term. All reported data concerned short-term treatment effects.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Mean improvement in a sleepiness scale, such as the Epworth Sleepiness Scale</HEADING>
<P>This outcome was available in four trials accounting for 101 patients (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>; <LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>; <LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>). In three cross-over trials, there were respectively, 40 (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>), 20 (<LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>) and 13 (<LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>) participants who underwent two measurements. The mean difference was -2.26 (95% CI -3.78 to -0.73) (random-effects model) in favor of modafinil with heterogeneity across the studies (I² = 84%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> ).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Mean improvement in the multiple sleep latency test</HEADING>
<P>In the randomized cross-over trial of selegiline (<LINK REF="STD-Antonini-1997" TYPE="STUDY">Antonini 1997</LINK>), there were 11 participants who had two measurements. The multiple sleep latency tests showed a mean difference of -3.68 minutes in favor of the control group (95% CI -3.99 to -3.37) (see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), which was not significant. This outcome was also available in one trial of modafinil (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>), the multiple sleep latency tests showed a mean difference of 0.15 (95% CI -1.18 to 1.48). The pooled estimate showed a mean difference of -1.82 (95% CI -5.57 to -1.93) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> ).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Ambulatory 24 hour sleep-wake monitoring</HEADING>
<P>We found no randomized trial testing this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Sleep studies, i.e. apnea-hypopnea index or mean oxygen saturation or the time spent with an arterial oxygen saturation below 90%</HEADING>
<P>In two randomized trials (<LINK REF="STD-Antonini-1997" TYPE="STUDY">Antonini 1997</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>), polysomnographic recordings were performed but the results were not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Quality of life scale</HEADING>
<P>In one study (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>), the Profile and Mood States scale and the SF 36-item Health Survey were used. There was no evidence for any substantial benefit from modafinil (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In two studies (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>), modafinil did not result in any significant changes in the mean improvement in the total score of SF36) (1.27, 95% CI: -3.63 to 6.17, random-effects model) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). In another study, quality of life was assessed using the RAND-36 scale (<LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>). There was no evidence for any benefit from modafinil.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Adverse events</HEADING>
<P>In one of the randomized trials identified (<LINK REF="STD-Antonini-1997" TYPE="STUDY">Antonini 1997</LINK>), one of the 11 participants dropped out voluntarily because of poor compliance. In the remaining ten, treatment with selegiline was associated with irritability in two participants and slight difficulty in micturition in one male patient. In these participants, side effects never required discontinuation of the study drug or specific treatment.</P>
<P>In the <LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK> study, 30 participants reported a total of 83 adverse events (65 on modafinil and 18 on placebo), mostly during the first week of treatment. Adverse events that were reported more than once included headache (n = 15), anorexia (n = 6), nausea (n = 6), insomnia (n = 5), anxiety (n = 4), dry mouth (n = 4), dyspepsia (n = 4), dizziness (n = 3), nervousness (n = 3), and tachycardia (n = 2). A total of four randomized participants withdrew from the study, one during the placebo trial in the first week for a reason which was not drug related, and three due to adverse events, one in the placebo group and two in the treated group.</P>
<P>In the third study, no participants withdrew due to adverse events, but one participant withdrew before the final visit for a reason which was not drug related (<LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>).</P>
<P>In the fourth study, the authors did not report any adverse events (<LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>).</P>
<P>In the fifth study, there were 8 patients (4 in each arm) who experienced at least one adverse event, and no participants withdrew due to adverse events (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-01-19 16:58:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>Although daytime sleepiness is a common symptom of myotonic dystrophy (<LINK REF="REF-Rubinsztein-1998" TYPE="REFERENCE">Rubinsztein 1998</LINK>), there have only been five trials that addressed the efficacy of psychostimulants. One failed to demonstrate any beneficial effect of selegiline, a monoamine oxidase B inhibitor. There were several pitfalls in this trial that may not allow one to draw any final conclusion. The trial only included ten evaluable patients. Among these patients presumed to have excessive daytime sleepiness on the basis of a self questionnaire assessment, four patients failed to meet criteria for hypersomnia during the multiple sleep latency tests, i.e. their values for sleep latencies were more than 20 minutes. This highlights the need for a robust diagnostic test of hypersomnia such as the multiple sleep latency test or the maintenance of wakefulness test for both the screening of patients to be enrolled in a trial and the assessment of treatment efficacy. Finally, the dose of selegiline was only 20 mg daily which is less than is commonly used in idiopathic hypersomnia (<LINK REF="REF-Hublin-1994" TYPE="REFERENCE">Hublin 1994</LINK>).</P>
<P>Four trials have evaluated modafinil (<LINK REF="STD-MacDonald-2002" TYPE="STUDY">MacDonald 2002</LINK>; <LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>; <LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>; <LINK REF="STD-Wintzen-2007" TYPE="STUDY">Wintzen 2007</LINK>). These trials except one (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>) suggested that modafinil improved patients' sleepiness and was well-tolerated. Nevertheless, none of these three trials used the conventional maintenance of wakefulness test (<LINK REF="REF-Mitler-1982" TYPE="REFERENCE">Mitler 1982</LINK>). In one trial the authors used a modified maintenance of wakefulness test in which there were no electroencephalographic recordings and assessment of sleep onset relied on behavioral criteria (<LINK REF="STD-Talbot-2003" TYPE="STUDY">Talbot 2003</LINK>). Patients were asked to tap a proximity detector with a finger repeatedly in response to a dim red light-emitting diode flashing every three seconds. A failure to respond for 21 seconds was considered as reflecting onset of sleep. This might not be valid in patients with myotonia or cognitive dysfunction. In this study, although post-treatment absolute values were better in the modafinil group than in the placebo group, the changes from baseline were not significantly different between the two treatment arms for the modified maintenance of wakefulness test, for the Epworth Sleepiness Scale or for the various components of the SF36 scale. The only trial that used conventional maintenance of wakefulness test found no evidence that modafinil significantly improved daytime sleepiness in myotonic dystrophy (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>).</P>
<P>The meta-analysis of data from the four trials comparing modafinil to a placebo found no significant benefit from this drug on objective assessment of daytime sleepiness. Nevertheless, there was a significant improvement in patients perception of hypersomnia as indicated by reduction in the score of the Epworth Sleepiness Scale in modafinil-treated patients (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Of note, all these trials were small sized and investigated short-term effects of treatment on daytime sleepiness.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-12-14 13:03:44 +0000" MODIFIED_BY="Kate Jewitt">
<IMPLICATIONS_PRACTICE MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt">
<P>According to low quality evidence, psychostimulants do not improve excessive daytime sleepiness in myotonic dystrophy. Also according to low quality evidence, the only benefit observed with modafinil from multiple measures in adults with myotonic dystrophy, was improved daytime sleepiness as assessed by the Epworth Sleepiness scale. There is no evidence about the efficacy of psychostimulants in children with myotonic dystrophy and excessive somnolence.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-12-14 13:03:44 +0000" MODIFIED_BY="Kate Jewitt">
<P>The short-term and long-term efficacy and safety of psychostimulants, particularly modafinil, in myotonic dystrophy still remain to be adequately tested in randomized trials.</P>
<P>The primary outcome measure for randomized trials on psychostimulants in myotonic dystrophy should be a reliable index of somnolence, such as the maintenance of wakefulness test.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-02-10 11:02:25 +0000" MODIFIED_BY="Ruth Brassington">
<P>Our thanks to Philip Barnes, Cardiac/Neuro Care Group, King's College Hospital, London UK, who was co-author on the protocol, the first published version of this review and the 2006 update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-02-10 11:22:56 +0000" MODIFIED_BY="Ruth Brassington">
<P>One of the authors (DA) was an investigator in one of the included trials (<LINK REF="STD-Orlikowski-2009" TYPE="STUDY">Orlikowski 2009</LINK>) which was funded by the Association Française de lutte contre les Myopathies and by Lafon pharmaceutical company.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-01-19 16:56:42 +0000" MODIFIED_BY="Kate Jewitt">
<P>Potentially relevant papers were scrutinized by two authors (Djillali Annane and Robert Miller) and the selection of eligible studies was agreed by them. Data were extracted by one author (Djillali Annane) and checked by other authors (Dan Moore, Robert Miller). Dan Moore was responsible for statistical analyses from unpublished data provided by primary authors of papers. All authors agreed the final text.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-12-14 13:04:01 +0000" MODIFIED_BY="Kate Jewitt">
<P>In the 2010 update, we updated the risk of bias methodology in accordance with the 2008 edition of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) and included a 'Summary of findings' table. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-12-14 13:08:17 +0000" MODIFIED_BY="Kate Jewitt">
<STUDIES MODIFIED="2010-12-14 13:07:39 +0000" MODIFIED_BY="Kate Jewitt">
<INCLUDED_STUDIES MODIFIED="2010-12-14 13:07:39 +0000" MODIFIED_BY="Kate Jewitt">
<STUDY DATA_SOURCE="PUB" ID="STD-Antonini-1997" MODIFIED="2010-02-10 13:47:13 +0000" MODIFIED_BY="Ruth Brassington" NAME="Antonini 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-02-10 13:47:13 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Antonini G, Morino S, Fiorelli M, Fiorini M, Giubilei F</AU>
<TI>Selegiline in the treatment of hypersomnolence in myotonic dystrophy: a pilot study</TI>
<SO>Journal of Neuroscience</SO>
<YR>1997</YR>
<VL>147</VL>
<NO>2</NO>
<PG>167-9</PG>
<IDENTIFIERS MODIFIED="2010-02-10 13:47:13 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2010-02-10 13:47:13 +0000" MODIFIED_BY="Ruth Brassington" TYPE="MEDLINE" VALUE="97260024"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MacDonald-2002" NAME="MacDonald 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MacDonald JR, Hill JD, Tarnopolsky MA</AU>
<TI>Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>12</NO>
<PG>1876-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Orlikowski-2009" MODIFIED="2010-12-14 13:07:39 +0000" MODIFIED_BY="Kate Jewitt" NAME="Orlikowski 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-12-14 13:07:39 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Orlikowski D, Chevret S, Quera Salva MA, Laforêt P, Lofaso F, Verschueren A et al</AU>
<TI>Modafinil for the treatment of excessive daytime sleepiness in myotonic dystrophy: a randomised, double-blind, placebo-controlled trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>8</NO>
<PG>1765-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-06-22 11:49:45 +0100" MODIFIED_BY="Djillali Annane"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Talbot-2003" NAME="Talbot 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Talbot K, Stradling J, Crosby J, Hilton-Jones D</AU>
<TI>Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>5</NO>
<PG>357-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Wintzen-2007" MODIFIED="2010-02-10 13:48:49 +0000" MODIFIED_BY="Ruth Brassington" NAME="Wintzen 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-02-10 13:48:49 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wintzen AR, Lammers GJ, van Dijk JG</AU>
<TI>Does modafinil enhance activity of patients with myotonic dystrophy?: a double-blind placebo-controlled crossover study</TI>
<SO>Journal of Neurology</SO>
<YR>2007</YR>
<VL>254</VL>
<NO>1</NO>
<PG>26-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-06-22 11:49:15 +0100" MODIFIED_BY="Djillali Annane"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-12-14 13:08:17 +0000" MODIFIED_BY="Kate Jewitt">
<ADDITIONAL_REFERENCES MODIFIED="2010-12-14 13:08:17 +0000" MODIFIED_BY="Kate Jewitt">
<REFERENCE ID="REF-Brook-1992" MODIFIED="2010-02-10 13:46:42 +0000" MODIFIED_BY="Ruth Brassington" NAME="Brook 1992" TYPE="JOURNAL_ARTICLE">
<AU>Brook JD, Mc Currach ME, Harley HG, Buckler AJ, Church D, Aburatini et al</AU>
<TI>Molecular basis of myotonic dystrophy expansion of a trinucleotide (CTG) repeat at the 3' end of a protein kinase family member</TI>
<SO>Cell</SO>
<YR>1992</YR>
<VL>68</VL>
<NO>4</NO>
<PG>799-808</PG>
<IDENTIFIERS MODIFIED="2010-02-10 13:46:41 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2010-02-10 13:46:36 +0000" MODIFIED_BY="Ruth Brassington" TYPE="MEDLINE" VALUE="92154692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Buxton-1992" NAME="Buxton 1992" TYPE="JOURNAL_ARTICLE">
<AU>Buxton J, Shelbourne P, Davies J, Jones L, Van Tongeren T, Aslanidis C et al</AU>
<TI>Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy</TI>
<SO>Nature</SO>
<YR>1992</YR>
<VL>355</VL>
<NO>6360</NO>
<PG>547-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92158048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-B_x00e9_gin-1997" NAME="Bégin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bégin P, Mathieu J, Almirall J, Grassino A</AU>
<TI>Relationship between chronic hypercapnia and inspiratory muscle weakness in myotonic dystrophy</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>156</VL>
<NO>1</NO>
<PG>133-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97374288"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carskadon-1986" NAME="Carskadon 1986" TYPE="JOURNAL_ARTICLE">
<AU>Carskadon MA, Dement WC, Mitler MN, Roth R, Westbrook PR, Keenan S</AU>
<TI>Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness</TI>
<SO>Sleep</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>4</NO>
<PG>519-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87119689"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Damian-2001" NAME="Damian 2001" TYPE="JOURNAL_ARTICLE">
<AU>Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichman H</AU>
<TI>Modafinil for excessive daytime sleepiness in myotonic dystrophy</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>6</NO>
<PG>794-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunne-1994" NAME="Dunne 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dunne PW, Walch ET, Epstein HF</AU>
<TI>Phosphorylation reactions of recombinant human myotonic dystrophy protein kinase and their inhibition</TI>
<SO>Biochemistry</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>35</NO>
<PG>10809-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94355306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fu-1992" NAME="Fu 1992" TYPE="JOURNAL_ARTICLE">
<AU>Fu YH, Pizzutti A, Fenwick RG Jr, King JR, Rajnarayan S, Dunne PW et al</AU>
<TI>An unstable triplet repeat in a gene related to myotonic dystrophy</TI>
<SO>Science</SO>
<YR>1992</YR>
<VL>255</VL>
<NO>5049</NO>
<PG>1256-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92188202"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gillam-1964" NAME="Gillam 1964" TYPE="JOURNAL_ARTICLE">
<AU>Gillam PMS, Heaf PJD, Kaufman L, Lucas BGD</AU>
<TI>Respiration in dystrophia myotonica</TI>
<SO>Thorax</SO>
<YR>1964</YR>
<VL>19</VL>
<PG>112-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilmartin-1991" NAME="Gilmartin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gilmartin JJ, Cooper BG, Griffiths CJ, Walls TJ, Veale D, Stone TN et al</AU>
<TI>Breathing during sleep in patients with myotonic dystrophy and non-myotonic respiratory muscle weakness</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>285</NO>
<PG>21-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94218426"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Griggs-1989" NAME="Griggs 1989" TYPE="JOURNAL_ARTICLE">
<AU>Griggs RC, Wood DS, Working Group on the Molecular Defect in Myotonic Dystrophy</AU>
<TI>Criteria for establishing the validity of genetic recombination in myotonic dystrophy</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39</VL>
<NO>3</NO>
<PG>420-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89182492"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guilleminault-1978" NAME="Guilleminault 1978" TYPE="JOURNAL_ARTICLE">
<AU>Guilleminault C, Cummiskey J, Motta J, Lynne-Davies P</AU>
<TI>Respiratory and haemodynamic study during wakefulness and sleep in myotonic dystrophy</TI>
<SO>Sleep</SO>
<YR>1978</YR>
<VL>1</VL>
<NO>1</NO>
<PG>19-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80036025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harley-1992" NAME="Harley 1992" TYPE="JOURNAL_ARTICLE">
<AU>Harley HG, Brook JO, Rundle SA, Crow S, Readon W, Buckler AJ et al</AU>
<TI>Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy</TI>
<SO>Nature</SO>
<YR>1992</YR>
<VL>355</VL>
<NO>6360</NO>
<PG>545-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92158047"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harper-1979" NAME="Harper 1979" TYPE="BOOK">
<AU>Harper P</AU>
<SO>Myotonic Dystrophy: Major Problems in Neurology</SO>
<YR>1979</YR>
<VL>9</VL>
<PB>WB Saunders Co</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-12-14 13:08:17 +0000" MODIFIED_BY="Kate Jewitt" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009.</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hublin-1994" NAME="Hublin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hulin C, Partinen N, Heinonen EH, Puuka P, Salmi T</AU>
<TI>Selegiline in the treatment of narcolepsy</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>11</NO>
<PG>2095-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johns-1991" MODIFIED="2010-02-10 13:50:20 +0000" MODIFIED_BY="Ruth Brassington" NAME="Johns 1991" TYPE="JOURNAL_ARTICLE">
<AU>Johns MN</AU>
<TI>A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale</TI>
<SO>Sleep</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>6</NO>
<PG>540-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahadevan-1992" MODIFIED="2010-02-10 13:57:47 +0000" MODIFIED_BY="Ruth Brassington" NAME="Mahadevan 1992" TYPE="JOURNAL_ARTICLE">
<AU>Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G et al</AU>
<TI>Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene</TI>
<SO>Science</SO>
<YR>1992</YR>
<VL>255</VL>
<NO>5049</NO>
<PG>1253-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92188201"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manni-1991" NAME="Manni 1991" TYPE="JOURNAL_ARTICLE">
<AU>Manni R, Zucca C, Martinetti M, Ottolini A, Lanzi G, Tartara A</AU>
<TI>Hypersomnia in dystrophia myotonica: a neurophysiological and immunogenetic study</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1991</YR>
<VL>84</VL>
<NO>6</NO>
<PG>498-502</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92170282"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mitler-1982" NAME="Mitler 1982" TYPE="JOURNAL_ARTICLE">
<AU>Mitler MM, Gujavarty KS, Browman CP</AU>
<TI>Maintenance of wakefulness test: a polysomnographic technique for evaluating treatment in patients with excessive somnolence</TI>
<SO>Electroencephalography Clinical Neurophysiology</SO>
<YR>1982</YR>
<VL>53</VL>
<NO>6</NO>
<PG>658-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82210437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ono-1998" MODIFIED="2010-02-10 13:57:49 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ono 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ono S, Takahashi K, Jinnai K, Kanda F, Fukuoka Y, Kurisaki H et al</AU>
<TI>Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>2</NO>
<PG>535-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98145387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rubinsztein-1998" NAME="Rubinsztein 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rubinsztein JS, Rubinsztein DC, Goodburn S, Holland AJ</AU>
<TI>Apathy and hypersomnia are common features of myotonic dystrophy</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1998</YR>
<VL>64</VL>
<NO>4</NO>
<PG>510-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98236082"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Mech_x00e9_-1994" NAME="Van der Meché 1994" TYPE="JOURNAL_ARTICLE">
<AU>Van der Meché FGA, Bogaard JM, Van der Sluys JCM, Schimsheimer RJ, Ververs CCM, Busch HFM</AU>
<TI>Daytime sleep in myotonic dystrophy is not caused by sleep apnoea</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>5</NO>
<PG>626-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94260222"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-12-14 13:05:59 +0000" MODIFIED_BY="Kate Jewitt">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-12-14 13:05:59 +0000" MODIFIED_BY="Kate Jewitt" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Antonini-1997">
<CHAR_METHODS MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt">
<P>Single centre, double blind, placebo-controlled, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:57:35 +0000" MODIFIED_BY="Kate Jewitt">
<P>n = 11 adults with myotonic dystrophy and excessive daytime sleepiness. One participant dropped out for poor compliance</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 15:57:38 +0000" MODIFIED_BY="Kate Jewitt">
<P>Selegiline 20 mg daily for 30 days, or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Multiple sleep latency test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-MacDonald-2002">
<CHAR_METHODS MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt">
<P>Single centre,<BR/>double blind, placebo-controlled, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt">
<P>n = 40 adults with myotonic dystrophy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 15:57:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>Two periods of two weeks of treatment with modafinil (or a placebo) 100 mg in the morning and 100 mg in the evening for one week, then 200 mg in the morning and 100 mg in the evening for one week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome measure:<BR/>Epworth Sleepiness Scale,<BR/>Secondary outcome measures:<BR/>1) Standford Sleepiness Scale<BR/>2) vigour-activity and fatigue-inertia factors of the profile of mood states<BR/>3) RAND 36-Item Health Survey<BR/>4) voluntary strength<BR/>5) adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-14 13:05:03 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Orlikowski-2009">
<CHAR_METHODS MODIFIED="2010-12-14 12:38:38 +0000" MODIFIED_BY="Kate Jewitt">
<P>Multicentre, randomized placebo-controlled trial on two parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt">
<P>n = 28 adults with myotonic dystrophy with excessive sleepiness assessed by an multiple sleep latency test of less than 8 minutes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-22 11:49:15 +0100" MODIFIED_BY="Djillali Annane">
<P>Modafinil 300 mg daily for one month or its placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-14 13:05:03 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary outcome: Mean improvement in maintenance of wakefulness test</P>
<P>Secondary outcomes:</P>
<P>(1) Mean latency of multiple sleep latency test</P>
<P>(2) Epworth Sleepiness Scale</P>
<P>(3) Global patients self assessment and physician assessment of therapeutic effect using a visual analogue scale (VAS) graduated from 0 (no effect) to 100 (full recovery from excessive daytime sleepiness)</P>
<P>(4) Disturbances of personality and mood as assessed by Hamilton scale</P>
<P>(5) Quality of life as assessed by the SF36 scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-22 11:49:15 +0100" MODIFIED_BY="Djillali Annane"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-14 12:09:06 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Talbot-2003">
<CHAR_METHODS MODIFIED="2010-12-14 12:09:06 +0000" MODIFIED_BY="Kate Jewitt">
<P>Single centre,<BR/>double blind, placebo-controlled, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-14 12:09:06 +0000" MODIFIED_BY="Kate Jewitt">
<P>n = 20 adults with myotonic dystrophy and an Epworth Sleepiness Scale score of 10 or more</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 15:58:27 +0000" MODIFIED_BY="Kate Jewitt">
<P>Modafinil, single morning dose of 100 mg on days 1 to 5, then 200 mg on days 6 to 28, or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-10 11:07:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome measure:<BR/>(1) Epworth Sleepiness Scale,<BR/>(2) Modified maintenance of wakefulness test *<BR/>Secondary outcome measures:<BR/>(1) Driving stimulator test +<BR/>(2) Activity diary<BR/>(3) Short Form 36<BR/>(4) Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-14 12:38:39 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Wintzen-2007">
<CHAR_METHODS MODIFIED="2010-12-14 12:38:39 +0000" MODIFIED_BY="Kate Jewitt">
<P>Single-centre, randomized cross-over, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 16:00:07 +0000" MODIFIED_BY="Kate Jewitt">
<P>n = 13 adults with myotonic dystrophy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-10 11:08:35 +0000" MODIFIED_BY="Ruth Brassington">
<P>Two periods of two weeks of treatment with modafinil (or a placebo) 200 mg per day for one week, then either 200 or 400 mg for one week according to patients perception of efficacy and tolerance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-10 11:08:39 +0000" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: score based on structured interview (range from 0 to 5)</P>
<P>Secondary outcomes: RAND-36; Epworth Sleepiness Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>* Modified maintenance of wakefulness test: sleep onset was not assessed by electroencephalographic (as for the conventional test) but by behavioral criteria.<BR/>+ Driving stimulator test: a test of alertness used in studies of obstructive sleep apnea. It uses a computer to simulate car driving at night.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-06-22 11:49:15 +0100" MODIFIED_BY="Djillali Annane" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-12-14 13:05:59 +0000" MODIFIED_BY="Kate Jewitt">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-12-14 12:17:06 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-14 12:17:05 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Antonini-1997">
<DESCRIPTION>
<P>The randomization list was generated by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-14 12:17:05 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-MacDonald-2002">
<DESCRIPTION>
<P>The randomization list was generated by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-14 12:17:06 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Orlikowski-2009">
<DESCRIPTION>
<P>The randomization list was generated by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-14 12:17:06 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Talbot-2003">
<DESCRIPTION>
<P>The randomization list was generated by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:08:41 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Wintzen-2007">
<DESCRIPTION>
<P>Not given in the manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-02-10 11:08:52 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:06:53 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Antonini-1997">
<DESCRIPTION>
<P>Coded serial identical containers were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:04:11 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-MacDonald-2002">
<DESCRIPTION>
<P>Coded serial identical containers </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:07:52 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Orlikowski-2009">
<DESCRIPTION>
<P>Coded serial identical containers were used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:07:29 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Talbot-2003">
<DESCRIPTION>
<P>Coded serial identical containers were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:08:52 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Wintzen-2007">
<DESCRIPTION>
<P>There was no detail on the method used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-02-10 11:08:58 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-10 11:04:42 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Antonini-1997">
<DESCRIPTION>
<P>Identical appearing placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-10 11:04:21 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-MacDonald-2002">
<DESCRIPTION>
<P>Indistinguishable placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-10 11:07:51 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Orlikowski-2009">
<DESCRIPTION>
<P>Indistinguishable placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-10 11:08:03 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Talbot-2003">
<DESCRIPTION>
<P>Indistinguishable placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-10 11:08:58 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Wintzen-2007">
<DESCRIPTION>
<P>Indistinguishable placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-12-14 13:05:59 +0000" MODIFIED_BY="Kate Jewitt" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-10 11:03:47 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Antonini-1997">
<DESCRIPTION>
<P>Data are given for all outcomes described in the method section. No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-14 12:09:05 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-MacDonald-2002">
<DESCRIPTION>
<P>Data are given for all outcomes described in the method section. No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-10 11:07:43 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Orlikowski-2009">
<DESCRIPTION>
<P>Data are given for all outcomes described in the method section. No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-14 13:05:35 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Talbot-2003">
<DESCRIPTION>
<P>Data are given for all outcomes described in the method section. None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-14 13:05:59 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Wintzen-2007">
<DESCRIPTION>
<P>Data are given for all outcomes described in the method section. None lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-12-07 15:58:36 +0000" MODIFIED_BY="Kate Jewitt" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 15:57:46 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Antonini-1997">
<DESCRIPTION>
<P>The protocol was not available. Thus it is not clear if reported outcomes were a priori defined and if all a priori defined outcomes were indeed reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 15:58:06 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-MacDonald-2002">
<DESCRIPTION>
<P>The protocol was not available. Thus it is not clear if reported outcomes were a priori defined and if all a priori defined outcomes were indeed reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 15:58:19 +0000" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Orlikowski-2009">
<DESCRIPTION>
<P>The protocol was available and all comparisons and outcomes reported in the manuscript matched those stated in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 15:58:36 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Talbot-2003">
<DESCRIPTION>
<P>The protocol was not available. Thus it is not clear if reported outcomes were a priori defined and if all a priori defined outcomes were indeed reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:09:05 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Wintzen-2007">
<DESCRIPTION>
<P>The protocol was not available. Thus it is not clear if reported outcomes were a priori defined and if all a priori defined outcomes were indeed reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-02-10 11:09:30 +0000" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:03:54 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Antonini-1997">
<DESCRIPTION>
<P>No evidence for protocol violation - the study was not stopped prematurely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:05:22 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-MacDonald-2002">
<DESCRIPTION>
<P>No evidence for protocol violation - the study was not stopped prematurely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:07:35 +0000" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Orlikowski-2009">
<DESCRIPTION>
<P>The study was interrupted prematurely for slow recruitment rate and drug expiration dates </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:08:18 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Talbot-2003">
<DESCRIPTION>
<P>No evidence for protocol violation - the study was not stopped prematurely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:09:30 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Wintzen-2007">
<DESCRIPTION>
<P>No evidence for protocol violation - the study was not stopped prematurely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-01-04 16:17:49 +0000" MODIFIED_BY="Kate Jewitt">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-01-04 16:17:49 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-01-04 16:17:49 +0000" MODIFIED_BY="Grade Profiler">Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy<BR/>
<B>Settings:</B> outpatients<BR/>
<B>Intervention:</B> Psychostimulants<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Psychostimulants</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>improvement in the maintenance of wakefulness test</B>
<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean improvement in the maintenance of wakefulness test in the intervention groups was<BR/>
<B>2.11 higher</B>
<BR/>(1.98 lower to 6.21 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>improvement in the Epworth Sleepiness Score</B>
<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean improvement in the Epworth Sleepiness Score in the intervention groups was<BR/>
<B>2.26 lower</B>
<BR/>(3.78 to 0.73 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>101<BR/>(4 studies<SUP>3</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>improvement in multiple sleep latency test</B>
<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean improvement in multiple sleep latency test in the intervention groups was<BR/>
<B>1.82 lower</B>
<BR/>(5.57 lower to 1.93 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(2 studies<SUP>4</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>quality of life scale - mean improvement in total score of Short Form 36</B>
<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life scale - mean improvement in total score of Short Form 36 in the intervention groups was<BR/>
<B>1.27 higher</B>
<BR/>(3.63 lower to 6.17 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(2 studies<SUP>4</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> There was some heterogeneity in the results that we could not explain<BR/>
<SUP>2</SUP> Studies had a small sample size<BR/>
<SUP>3</SUP> 3 studies had a crossover design: Talbot 2003 (n=20), MacDonald 2002 (n=40), and Wintzen, 2007 (n=13)<BR/>
<SUP>4</SUP> Study by Talbot 2003 had a crossover design, n=20</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-01-19 16:49:38 +0000" MODIFIED_BY="Kate Jewitt">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-19 16:49:38 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<TITLE>Quality of life in the MacDonald 2002 study</TITLE>
<TABLE COLS="6" ROWS="17">
<TR>
<TH>
<P>Scales</P>
</TH>
<TH>
<P>Mean Delta Placebo</P>
</TH>
<TH>
<P>SD Delta Placebo</P>
</TH>
<TH>
<P>Mean Delta Modafinil</P>
</TH>
<TH>
<P>SD Delta Modafinil</P>
</TH>
<TH>
<P>2 sided P-values</P>
</TH>
</TR>
<TR>
<TD>
<P>Profile of Mood States (POMS)<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Anger/Hostility<BR/>
<BR/>
</P>
</TD>
<TD>
<P>-0.41<BR/>
</P>
</TD>
<TD>
<P>1.46<BR/>
</P>
</TD>
<TD>
<P>-1.25<BR/>
</P>
</TD>
<TD>
<P>2.98<BR/>
</P>
</TD>
<TD>
<P>0.15<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Confusion/Bewilderment<BR/>
</P>
</TD>
<TD>
<P>0.67<BR/>
</P>
</TD>
<TD>
<P>1.27<BR/>
</P>
</TD>
<TD>
<P>-0.69<BR/>
</P>
</TD>
<TD>
<P>2.24<BR/>
</P>
</TD>
<TD>
<P>0.003<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Depression/Dejection<BR/>
</P>
</TD>
<TD>
<P>-0.35<BR/>
</P>
</TD>
<TD>
<P>2.13<BR/>
</P>
</TD>
<TD>
<P>-0.71<BR/>
</P>
</TD>
<TD>
<P>2.41<BR/>
</P>
</TD>
<TD>
<P>0.52<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Fatigue/Inertia<BR/>
</P>
</TD>
<TD>
<P>-0.88<BR/>
</P>
</TD>
<TD>
<P>3.67<BR/>
</P>
</TD>
<TD>
<P>-1.85<BR/>
</P>
</TD>
<TD>
<P>3.77<BR/>
</P>
</TD>
<TD>
<P>0.29<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Tension/Anxiety<BR/>
</P>
</TD>
<TD>
<P>-0.26<BR/>
</P>
</TD>
<TD>
<P>1.40<BR/>
</P>
</TD>
<TD>
<P>-0.41<BR/>
</P>
</TD>
<TD>
<P>3.67<BR/>
</P>
</TD>
<TD>
<P>0.83<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Vigour/Activity<BR/>
</P>
</TD>
<TD>
<P>0.62<BR/>
</P>
</TD>
<TD>
<P>3.67<BR/>
</P>
</TD>
<TD>
<P>-0.79<BR/>
</P>
</TD>
<TD>
<P>3.43<BR/>
</P>
</TD>
<TD>
<P>0.11<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>RAND 36-Item Health Survey Score<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Physical Functioning<BR/>
</P>
</TD>
<TD>
<P>6.53<BR/>
</P>
</TD>
<TD>
<P>18.50<BR/>
</P>
</TD>
<TD>
<P>6.47<BR/>
</P>
</TD>
<TD>
<P>19.77<BR/>
</P>
</TD>
<TD>
<P>0.99<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Role Limitations Due to Physical Health<BR/>
</P>
</TD>
<TD>
<P>12.18<BR/>
</P>
</TD>
<TD>
<P>29.70<BR/>
</P>
</TD>
<TD>
<P>14.62<BR/>
</P>
</TD>
<TD>
<P>43.79<BR/>
</P>
</TD>
<TD>
<P>0.78<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Role Limitations Due to Emotional Problems<BR/>
</P>
</TD>
<TD>
<P>13.89<BR/>
</P>
</TD>
<TD>
<P>29.60<BR/>
</P>
</TD>
<TD>
<P>7.41<BR/>
</P>
</TD>
<TD>
<P>45.53<BR/>
</P>
</TD>
<TD>
<P>0.47<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Energy/Fatigue<BR/>
</P>
</TD>
<TD>
<P>3.89<BR/>
</P>
</TD>
<TD>
<P>21.16<BR/>
</P>
</TD>
<TD>
<P>20.14<BR/>
</P>
</TD>
<TD>
<P>24.12<BR/>
</P>
</TD>
<TD>
<P>0.003<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Emotional Well Being<BR/>
</P>
</TD>
<TD>
<P>6.78<BR/>
</P>
</TD>
<TD>
<P>21.43<BR/>
</P>
</TD>
<TD>
<P>6.42<BR/>
</P>
</TD>
<TD>
<P>14.98<BR/>
</P>
</TD>
<TD>
<P>0.94<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Social Functioning<BR/>
</P>
</TD>
<TD>
<P>8.03<BR/>
</P>
</TD>
<TD>
<P>25.41<BR/>
</P>
</TD>
<TD>
<P>3.48<BR/>
</P>
</TD>
<TD>
<P>20.49<BR/>
</P>
</TD>
<TD>
<P>0.45<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain<BR/>
</P>
</TD>
<TD>
<P>6.67<BR/>
</P>
</TD>
<TD>
<P>25.14<BR/>
<BR/>
</P>
</TD>
<TD>
<P>8.89<BR/>
<BR/>
</P>
</TD>
<TD>
<P>18.66<BR/>
<BR/>
</P>
</TD>
<TD>
<P>0.68<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>General Health<BR/>
</P>
</TD>
<TD>
<P>4.19<BR/>
</P>
</TD>
<TD>
<P>18.36</P>
</TD>
<TD>
<P>1.81</P>
</TD>
<TD>
<P>14.35</P>
</TD>
<TD>
<P>0.55</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Delta stands for the difference between study day 14 and baseline.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-01-19 16:49:02 +0000" MODIFIED_BY="Kate Jewitt">
<COMPARISON ID="CMP-001" MODIFIED="2011-01-19 16:49:02 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<NAME>Mean improvement in the maintenance of wakefulness test</NAME>
<IV_OUTCOME CHI2="2.6074665169620665" CI_END="7.369143574323168" CI_START="-2.3209082802055203" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.524117647058824" ESTIMABLE="YES" I2="61.6485966935794" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8674170180411612" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.402109593154398" MODIFIED="2010-08-12 18:57:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10636160771339276" P_Q="1.0" P_Z="0.30721453708551016" Q="0.0" RANDOM="YES" SCALE="11.661492869411516" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="8.017400000000002" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="1.0210842532623172">
<NAME>Mean improvement in the maintenance of wakefulness test</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="3.226351739283673" CI_START="-2.026351739283673" EFFECT_SIZE="0.6" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 10:30:04 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SE="1.34" STUDY_ID="STD-Orlikowski-2009" TOTAL_1="13" TOTAL_2="15" WEIGHT="62.27220299884659"/>
<IV_DATA CI_END="11.305496995784555" CI_START="0.09450300421544533" EFFECT_SIZE="5.7" ESTIMABLE="YES" ESTIMATE="5.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-12 18:46:06 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SE="2.86" STUDY_ID="STD-Talbot-2003" TOTAL_1="19" TOTAL_2="19" WEIGHT="37.727797001153405"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-08-05 12:17:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Secondary outcomes</NAME>
<IV_OUTCOME CHI2="18.35769591011442" CI_END="-0.7342302480379066" CI_START="-3.783449914745934" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="-2.2588400813919205" ESTIMABLE="YES" I2="83.6580798881895" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-08-05 12:13:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.7110764702597E-4" P_Q="1.0" P_Z="0.003685993531876794" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.7904899545340804" TOTALS="YES" TOTAL_1="84" TOTAL_2="87" WEIGHT="100.00000000000001" Z="2.9038545531509006">
<NAME>Mean improvement in the Epworth Sleepiness Scale</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-2.1472064827827904" CI_START="-2.8527935172172096" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 10:46:56 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SE="0.18" STUDY_ID="STD-MacDonald-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="33.194092460823235"/>
<IV_DATA CI_END="1.293576229796436" CI_START="-1.293576229796436" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 12:13:31 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SE="0.66" STUDY_ID="STD-Orlikowski-2009" TOTAL_1="12" TOTAL_2="15" WEIGHT="27.181820560964105"/>
<IV_DATA CI_END="0.33193877371809233" CI_START="-6.331938773718092" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 10:34:57 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SE="1.7" STUDY_ID="STD-Talbot-2003" TOTAL_1="19" TOTAL_2="19" WEIGHT="12.927958030994967"/>
<IV_DATA CI_END="-2.5476248506673627" CI_START="-5.252375149332638" EFFECT_SIZE="-3.9" ESTIMABLE="YES" ESTIMATE="-3.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 10:49:21 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.69" STUDY_ID="STD-Wintzen-2007" TOTAL_1="13" TOTAL_2="13" WEIGHT="26.696128947217705"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.059221311475408" CI_END="1.9296431484363135" CI_START="-5.573690145825347" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-1.822023498694517" ESTIMABLE="YES" I2="96.67323384848216" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2854770017568446" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-08-05 12:17:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.1906892511711646E-8" P_Q="1.0" P_Z="0.34116272403031933" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="7.090449999999995" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.9518704011610396">
<NAME>Mean improvement in multiple sleep latency test</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-3.3664057624735912" CI_START="-3.993594237526409" EFFECT_SIZE="-3.68" ESTIMABLE="YES" ESTIMATE="-3.68" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-25 19:28:42 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SE="0.16" STUDY_ID="STD-Antonini-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="51.48886419567929"/>
<IV_DATA CI_END="1.482775509487237" CI_START="-1.1827755094872372" EFFECT_SIZE="0.15" ESTIMABLE="YES" ESTIMATE="0.15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 12:17:16 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SE="0.68" STUDY_ID="STD-Orlikowski-2009" TOTAL_1="13" TOTAL_2="15" WEIGHT="48.51113580432071"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.23128080318578864" CI_END="6.165078466130381" CI_START="-3.631373581708414" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.2668524422109833" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.7899386084565808" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.10272603298487716" MODIFIED="2010-08-05 12:10:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6305757764278255" P_Q="1.0" P_Z="0.6122143311735722" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.00000000000001" Z="0.5069151869135953">
<NAME>Quality of life scale</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.23128080318578864" CI_END="6.165078466130381" CI_START="-3.631373581708414" DF="1" EFFECT_SIZE="1.2668524422109833" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.7899386084565808" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.10272603298487716" MODIFIED="2010-08-05 12:10:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6305757764278255" P_Z="0.6122143311735722" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.00000000000001" Z="0.5069151869135953">
<NAME>Mean improvement in total score of Short Form 36</NAME>
<IV_DATA CI_END="6.017507800422539" CI_START="-4.017507800422539" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 12:10:33 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SE="2.56" STUDY_ID="STD-Orlikowski-2009" TOTAL_1="13" TOTAL_2="15" WEIGHT="95.30189362304608"/>
<IV_DATA CI_END="29.278384741746823" CI_START="-15.918384741746824" EFFECT_SIZE="6.68" ESTIMABLE="YES" ESTIMATE="6.68" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-05 12:10:33 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SE="11.53" STUDY_ID="STD-Talbot-2003" TOTAL_1="19" TOTAL_2="19" WEIGHT="4.69810637695393"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-12-14 13:06:00 +0000" MODIFIED_BY="Kate Jewitt">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-12-14 13:06:00 +0000" MODIFIED_BY="Kate Jewitt" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASoAAAGACAIAAACV37jwAAARN0lEQVR42u3dvW7dRhPG8QO4SaHC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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-08-12 18:57:28 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Primary outcome: Maintenance of wakefulness test, outcome: 1.1 Mean improvement in the maintenance of wakefulness test.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAp8AAACQCAMAAAB5//DGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-08-05 12:18:15 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.1 Mean improvement in the Epworth Sleepiness Scale.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAp8AAACwCAMAAAB+U/XwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-08-05 12:18:27 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.2 Mean improvement in multiple sleep latency test.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAp8AAACQCAMAAAB5//DGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-08-05 12:18:46 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Secondary outcomes, outcome: 2.3 Quality of life scale.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAADQCAMAAADiQVNYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-12-14 12:38:58 +0000" MODIFIED_BY="Kate Jewitt">
<APPENDIX ID="APP-01" MODIFIED="2010-12-14 12:38:54 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<TITLE MODIFIED="2010-10-19 14:13:09 +0100" MODIFIED_BY="Angela Gunn">MEDLINE (OvidSP) Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-14 12:38:54 +0000" MODIFIED_BY="Kate Jewitt">
<P>1 randomised controlled trial.pt. <BR/>2 controlled clinical trial.pt. <BR/>3 randomized.ab.<BR/>4 placebo.ab.<BR/>5 drug therapy.fs. <BR/>6 randomly.ab. <BR/>7 trial.ab. <BR/>8 groups.ab. <BR/>9 or/1-8 <BR/>10 exp animals/ not humans.sh. <BR/>11 9 not 10 <BR/>12 (myotoni$ adj5 (dystroph$ or atroph$)).mp. <BR/>13 (steinert$ adj5 (disease$ or syndrome$)).mp. <BR/>14 Myotonic Dystrophy/ <BR/>15 or/12-14 <BR/>16 exp Central Nervous System Stimulants/ <BR/>17 (central adj5 stimulant$).mp. <BR/>18 (psychostimulant$ or caffeine or amphetamine$ or methylphenidate or selegiline or modafinil).mp. <BR/>19 or/16-18 <BR/>20 exp Disorders of Excessive Somnolence/ <BR/>21 (hypersomnia$ or somnolence$ or sleep$ or hypersomn$).mp. <BR/>22 exp Sleep Disorders/ <BR/>23 or/20-22 <BR/>24 11 and 15 and 19 and 23</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-12-14 12:38:58 +0000" MODIFIED_BY="Kate Jewitt" NO="2">
<TITLE MODIFIED="2010-10-19 14:13:38 +0100" MODIFIED_BY="Angela Gunn">EMBASE (OvidSP) Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-14 12:38:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>1 crossover-procedure/ <BR/>2 double-blind procedure/ <BR/>3 randomised controlled trial/ <BR/>4 single-blind procedure/ <BR/>5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).tw. <BR/>6 clinical trial/ <BR/>7 or/1-6 <BR/>8 animal/ not human/ <BR/>9 7 not 8 <BR/>10 Myotonic Dystrophy/<BR/>11 (myotoni$ adj5 (dystroph$ or atroph$)).mp. <BR/>12 (steinert$ adj5 (disease$ or syndrome$)).mp. <BR/>13 or/10-12 <BR/>14 exp Central Stimulant Agent/ <BR/>15 (central adj5 stimulant$).mp. <BR/>16 (psychostimulant$ or caffeine or amphetamine$ or methylphenidate or selegiline or modafinil).mp. <BR/>17 or/14-16 <BR/>18 exp Sleep Disorder/ <BR/>19 (hypersomnia$ or somnolence$ or hypersom$ or sleep$).mp. <BR/>20 18 or 19 <BR/>21 9 and 13 and 17 and 20</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-12-14 12:09:37 +0000" MODIFIED_BY="Kate Jewitt" NO="3">
<TITLE MODIFIED="2010-12-14 12:09:37 +0000" MODIFIED_BY="Kate Jewitt">Cochrane Central Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-14 12:09:06 +0000" MODIFIED_BY="Kate Jewitt">
<P>#1myotoni* AND (dystroph* OR atroph*)<BR/>#2(steinert* AND (disease* or syndrome*))<BR/>#3(#1 OR #2)<BR/>#4MeSH descriptor Central Nervous System Stimulants explode all trees<BR/>#5CENTRAL NEAR/5 STIMULANT*<BR/>#6(psychostimulant* OR caffeine OR amphetamine* OR methylphenidate OR selegiline OR modafinil)<BR/>#7(#4 OR #5 OR #6)<BR/>#8MeSH descriptor Disorders of Excessive Somnolence explode all trees<BR/>#9(hypersomnia* OR somnolence* OR sleep* OR hypersomn*)<BR/>#10MeSH descriptor Sleep Disorders explode all trees<BR/>#11(#8 OR #9 OR #10)<BR/>#12(#3 AND #7 AND #11)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>